4/23
04:30 pm
eols
Evolus to Report First Quarter Financial Results on May 7, 2024
Low
Report
Evolus to Report First Quarter Financial Results on May 7, 2024
4/17
04:19 pm
eols
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau® [Yahoo! Finance]
Low
Report
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau® [Yahoo! Finance]
4/17
04:05 pm
eols
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Low
Report
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
4/16
07:18 pm
eols
Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]
Low
Report
Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]
4/16
04:35 pm
eols
Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]
Low
Report
Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]
4/12
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/10
08:05 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
4/9
07:15 am
eols
Global Dermal Fillers Market Analysis Report 2023-2035: Minimally Invasive Nature and Launch of Products Targeting Specific Requirements Will Drive Growth [Yahoo! Finance]
Low
Report
Global Dermal Fillers Market Analysis Report 2023-2035: Minimally Invasive Nature and Launch of Products Targeting Specific Requirements Will Drive Growth [Yahoo! Finance]
4/6
10:20 am
eols
Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company [Yahoo! Finance]
Low
Report
Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company [Yahoo! Finance]
3/29
04:26 pm
eols
AEON Biopharma Announces Redemption of Public Warrants [Yahoo! Finance]
Low
Report
AEON Biopharma Announces Redemption of Public Warrants [Yahoo! Finance]
3/29
04:01 pm
eols
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/26
08:00 am
eols
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
3/20
02:27 pm
eols
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 [Seeking Alpha]
Low
Report
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 [Seeking Alpha]
3/19
04:42 pm
eols
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements [Yahoo! Finance]
Low
Report
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements [Yahoo! Finance]
3/19
04:42 pm
eols
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine [Yahoo! Finance]
Low
Report
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine [Yahoo! Finance]
3/11
07:35 am
eols
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock [Yahoo! Finance]
Medium
Report
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock [Yahoo! Finance]
3/11
07:29 am
eols
Evolus prices stock offering to raise about $50M [Seeking Alpha]
Medium
Report
Evolus prices stock offering to raise about $50M [Seeking Alpha]
3/11
07:00 am
eols
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Low
Report
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
3/10
09:37 am
eols
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report [Yahoo! Finance]
Low
Report
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report [Yahoo! Finance]
3/8
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/8
03:46 pm
eols
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
10:47 pm
eols
Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 [Yahoo! Finance]
Low
Report
Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 [Yahoo! Finance]
3/7
04:40 pm
eols
Evolus GAAP EPS of -$0.21 in-line, revenue of $61M in-line [Seeking Alpha]
Low
Report
Evolus GAAP EPS of -$0.21 in-line, revenue of $61M in-line [Seeking Alpha]
3/7
04:09 pm
eols
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance [Yahoo! Finance]
Low
Report
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance [Yahoo! Finance]
3/7
04:05 pm
eols
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
Medium
Report
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance